3-[2-(1-Benzyl-piperidin-4-ylamino)-phenyl]-propionamide | 131587-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-[2-(1-Benzyl-piperidin-4-ylamino)-phenyl]-propionamide
• CAS: 131587-34-3
• 化学式: C₂₁H₂₇N₃O
• 分子量: 337.465
• InChiKey: VVJNCGPOWGBCKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.18
• 重原子数：
  25.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  58.36
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  3-[2-(1-Benzyl-piperidin-4-ylamino)-phenyl]-propionamide 在 palladium on activated charcoal 盐酸 、 硫酸 、 氢气 、 potassium carbonate 、 一水合肼 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 异丙醇 为溶剂， 反应 15.5h， 生成 N-[3-[4-[[4-(3,4-二氢-2-氧代-1(2H)-喹啉基)-1-哌啶基]羰基]苯氧基]丙基]乙酰胺
  参考文献：
  名称：

  Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihydro-2(1H)-quinolinones

  摘要：

  A series of compounds has been synthesized and demonstrated to be antagonists of V1 receptors both in vitro and in vivo. These compounds are structurally related to the 1-(4-piperidyl)-2(1H)-quinolinones, including OPC-21268, an orally bioavailable AVP V1 antagonist with high V1 specificity. It has been found that the introduction of an acetamide group on the terminal alkoxy chain of 41-44 leads to an increase in oral activity. Certain of these compounds may have efficacy in the study of AVP V1 receptors.

  DOI：

  10.1021/jm00066a010
• 作为产物：
  描述：

  N-苄基哌啶酮 、 二氢肉桂酰胺 在 platinum(IV) oxide 氢气 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 3,4-二氢-2(1H)-喹啉酮 、 3-[2-(1-Benzyl-piperidin-4-ylamino)-phenyl]-propionamide
  参考文献：
  名称：

  Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihydro-2(1H)-quinolinones

  摘要：

  A series of compounds has been synthesized and demonstrated to be antagonists of V1 receptors both in vitro and in vivo. These compounds are structurally related to the 1-(4-piperidyl)-2(1H)-quinolinones, including OPC-21268, an orally bioavailable AVP V1 antagonist with high V1 specificity. It has been found that the introduction of an acetamide group on the terminal alkoxy chain of 41-44 leads to an increase in oral activity. Certain of these compounds may have efficacy in the study of AVP V1 receptors.

  DOI：

  10.1021/jm00066a010